Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium and Trichomonas vaginalis including relevant resistance-associated mutations in a single center in the Netherlands

[1]  F. V. Aar,et al.  Sexually transmitted infections in the Netherlands in 2019 , 2020 .

[2]  S. Bruisten,et al.  Simultaneous Detection of Neisseria gonorrhoeae and Fluoroquinolone Resistance Mutations to Enable Rapid Prescription of Oral Antibiotics , 2020, Sexually transmitted diseases.

[3]  S. Pereyre,et al.  Clinical Evaluation of Three Commercial PCR Assays for the Detection of Macrolide Resistance in Mycoplasma genitalium , 2019, Journal of Clinical Microbiology.

[4]  X. Beristain,et al.  Macrolide-Resistant Mycoplasma genitalium in Southeastern Region of the Netherlands, 2014–2017 , 2019, Emerging infectious diseases.

[5]  M. Rayment,et al.  British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium (2018) , 2019, International journal of STD & AIDS.

[6]  F. Hagen,et al.  Macrolide-Resistant Mycoplasma genitalium in Southeastern Region of the Netherlands, 2014–2017 , 2019, Emerging infectious diseases.

[7]  M. Unemo,et al.  Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  S. Pereyre,et al.  French Prospective Clinical Evaluation of the Aptima Mycoplasma genitalium CE-IVD Assay and Macrolide Resistance Detection Using Three Distinct Assays , 2017, Journal of Clinical Microbiology.

[9]  N. Low,et al.  Recent advances in the development and use of molecular tests to predict antimicrobial resistance in Neisseria gonorrhoeae , 2017, Expert review of molecular diagnostics.

[10]  F. Hagen,et al.  High prevalence of the A2058T macrolide resistance-associated mutation in Mycoplasma genitalium strains from the Netherlands , 2017, The Journal of antimicrobial chemotherapy.

[11]  C. Henquet,et al.  Multidrug-resistant Mycoplasma genitalium infections in Europe , 2017, European Journal of Clinical Microbiology & Infectious Diseases.

[12]  J. Veerbeek,et al.  Routine testing of Mycoplasma genitalium and Trichomonas vaginalis , 2017, Infectious diseases.

[13]  M. Cusini,et al.  2016 European guideline on Mycoplasma genitalium infections , 2016, Journal of the European Academy of Dermatology and Venereology.

[14]  J. Rahamat-Langendoen,et al.  Large two-centre study into the prevalence of Mycoplasma genitalium and Trichomonas vaginalis in the Netherlands , 2016, International journal of STD & AIDS.

[15]  M. Cusini,et al.  European guideline on Mycoplasma genitalium infections , 2016 .

[16]  S. Bruisten,et al.  Trichomonas vaginalis and Mycoplasma genitalium: age-specific prevalence and disease burden in men attending a sexually transmitted infections clinic in Amsterdam, the Netherlands , 2015, Sexually Transmitted Infections.

[17]  A. V. van Zwet,et al.  High levels of macrolide resistance-associated mutations in Mycoplasma genitalium warrant antibiotic susceptibility-guided treatment. , 2015, The Journal of antimicrobial chemotherapy.

[18]  M. Brouwers,et al.  Specific andSensitive Detection of Neisseria gonorrhoeae in ClinicalSpecimens by Real-Time PCR , 2005, Journal of Clinical Microbiology.

[19]  J. Jensen,et al.  Use of TaqMan 5′ Nuclease Real-Time PCR for Quantitative Detection of Mycoplasma genitalium DNA in Males with and without Urethritis Who Were Attendees at a Sexually Transmitted Disease Clinic , 2004, Journal of Clinical Microbiology.